Nagi Bioscience adds Dr Chris Radloff to its Board and announces closing of CHF1.8m seed financing

– SWITZERLAND, Lausanne –  Nagi Bioscience SA, a Swiss life-science-tech company developing a revolutionary technology for the in vitro testing of drugs and chemicals, today announced the closing of a CHF 1.8 million Seed financing round. Investors in the round include the leading Swiss venture capital platform investiere, Zürcher Kantonalbank, NEST pension fund and private investors from Switzerland and United States.

The proceeds of the financing round will be used to complete the development of Nagi Bioscience’s first product and prepare its market access.

Furthermore, the company announces the assignment of Dr. Chris Radloff to the Board of Directors. “I’m following Nagi Bioscience since more than a year and I’m excited to be part of the next phase developing this innovative idea between life science and microfluidics into a business”, says Dr. Radloff. Chris is a board director and angel investor in several start-up companies and brings to the company 20+ years of expertise in the life-science-tech field.

Nagi Bioscience, a spin-off from the Ecole Polytechnique Fédérale de Lausanne, was founded in January 2019. Nagi Bioscience has developed an innovative “Organism-on-Chip” technology, aiming to revolutionize the way toxic and beneficial effects of substances are tested today. This technology relies on the combined use of microfluidics and microscopic worms to provide a new sustainable alternative to traditional animal testing to pharma, chemical, cosmetic industries and biomedical research. This solution complies with the emerging directives for the replacement, reduction and refinement of animal testing, i.e. the so-called “3Rs” principles, and allows significantly reducing costs and delays of pharmaceutical and chemical research.

“Complex drug efficacy and safety tests that would take months using traditional animal testing now can be carried out on our microfluidic device in only a few days, at a fraction of their current cost and in a fully automated way” said Dr. Matteo Cornaglia, the founder and CEO of the company. “Nagi Bioscience is a great team of dedicated people sharing the vision to create a new class of solutions for faster, cost-effective and sustainable drug and chemical testing in the future. The whole team is excited and honored to get great investors on board that are sharing this vision and providing their expertise to accelerate commercialization and widespread use of our technology”.

Nagi Bioscience has already prototypes under validation in collaboration with key industrial players in the chemical and biotech fields. The proceeds of the seed round will allow completing product development and preparing market access.

About Nagi Bioscience SA

Nagi Bioscience SA was incorporated in January 2019 by Dr. Matteo Cornaglia, CEO, and Dr. Laurent Mouchiroud, CSO, as a spin-off of Ecole Polytechnique Fédérale de Lausanne with the vision of revolutionizing drug/chemical testing with innovative organism-on-chip technologies. Since its beginning as a startup project, Nagi Bioscience has been supported by various programs and institutions, including the Gebert Rüf Foundation, Venture Lab, the European Research Council, the Swiss National Science Foundation, Innosuisse, and the Novartis Foundation. In addition, Nagi Bioscience already won numerous awards, including PERL BioTech Prize, Swiss Laboratory Animal Science Association Award, PMEP Startup Competition and Fondation Egon Naef Award.

For more information: https://nagibio.ch

About Investiere

investiere is the leading European startup investment platform for qualified and institutional investors. Our investment professionals screen thousands of companies and present the best investment opportunities on our digital platform after a rigorous due diligence process. investiere focuses on European high-tech startups. The investiere community consists of more than 4’000 qualified private investors, family offices and pension funds. Furthermore, numerous Swiss corporates rely on investiere’s VC expertise to screen, select and invest in promising startups. With CHF 30 million invested in 2018, investiere is Switzerland’s most active startup investor. Zürcher Kantonalbank, the third-largest bank in Switzerland, is a minority shareholder of investiere.

For more information: https://www.investiere.ch

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Our Related Posts

Comments are closed.